Abstract
The trypanocidal activity of naturally occurring 6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (hispidin) prompted us to examine its cytotoxic activity toward normal and cancerous cells in culture. Hispidin synthesized in our laboratory to a high degree of purity (checked by 1H and 13C NMR spectroscopy) was shown to be cytotoxic (between 10-3 mol/L and 10-7 mol/L) toward normal human MRC-5 fibroblasts, human cancerous keratinocytes (SCL-1 cell line), and human cancerous pancreatic duct cells (Capan-1 cell line). Interestingly, addition of hispidin in three successive doses (between 10-5 mol/L and 10-7 mol/L) led to a 100-fold increase in activity with an enhanced activity on cancer cells compared to normal cells (50%). Synthetic hispidin was found to inhibit isoform β of protein kinase C (IC50 of 2 × 10-6 mol/L), but not E. coli and placental type XV alkaline phosphatases. The enhanced activity of hispidin toward the cancerous cell lines is discussed.
Similar content being viewed by others
References
Andreu JM, Gorbunoff MJ, Medrano FJ, Rossi M, Timasheff SN. Mechanism of colchicine binding to tubulin. Tolerance of substituents in ring-C′ of biphenyl analogs. Biochemistry. 1991;30:3777–86.
Ardalan B, Glazer R. An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev. 1981;8:157–67.
Bishop WR, Pachter JA, Pai JK. Regulation of phospholipid hydrolysis and 2nd messenger formation by protein kinase C. Adv Enzyme Regul.} 1992;32:177–92.
Blum RH, Carter SK. Adriamycin: a new anti-cancer drug with significant clinical activity. Ann Int Med. 1974;80:249–59.
Bollag GE, Roth RA, Beaudoin J, Mochly-Rosen D, Koshland DE. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci USA. 1986;83:5822–4.
Boukamp P, Tilgen W, Dzarlieva RT et al. Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J Natl Cancer Inst. 1982;68:415–22.
Boukamp P, Rupniak TR, Fusenig NE. Environmental mod-ulation of the expression of differentiation and malignancy in six human squamous cell carcinoma cell lines. Cancer Res. 1985;45:5582–92.
Brautigan DL. Protein phosphatases. Recent Prog Hormone Res. 1994;49:197-214.
Chadwich M, Rogers WI. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leuke-mia. Cancer Res. 1972;32:1045–56.
Chang BK. Differential sensitivity of pancreatic adenocarcino-ma cell lines to chemotherapeutic agents in culture. Cancer Treat Rev. 1983;67:355–61.
Cohen GL, Bauer WR, Barton JK, Lippard SJ. Binding of cis-and trans-dichlorodiammineplatinum (II) to DNA: evi-dence for unwinding and shortening of the double helix. Science. 1979;203:1014–6.
Cohen P. The discovery of protein phosphatases: from chaos and confusion to an understanding of their role in cell regulation and human disease. Bioassays. 1994;16:583–8.
Dechecchi MC, Tamanini A, Berton G, Cabrini G. Protein kinase C activates chloride conductance in C127 cells stably expressing the cystic fibrosis gene. J Biol Chem. 1993;268: 11321–5.
Edwards RL, Wilson DV. Constituents of the higher fungi. Part II. The synthesis of hispidin. J Chem Soc. 1961;4:5003–4.
Edwards RL, Lewis DG, Wilson DV. Constituents of the higher fungi. Part I. Hispidin, a new 4-hydroxy-6-styryl-2-pyrone from Polyporus hispidus. J Chem Soc. 1961;4:4995–5002.
Fögh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;59:221–6.
Gali RR, Pugazhenthi S, Chandelier RL. Reciprocal effects on the protein kinase C inhibitors staurosporine and H-7 on the regulation of glycol synthetase and phosphorases in the primary culture of hepatocytes. Metab Clin Exp. 1993;42: 1475–80.
Gonda Y, Nishizawa K, Ando S et al. Involvement of protein kinase-C in the regulation of assembly-disassembly of neurofilaments in vitro. Biochem Biophys Res Commun. 1990;167:1316–25.
Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hikada H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Bio-chem Pharmacol. 1988;37:2987–92.
Hartmann KU, Heidelberger C. Studies on fluorinated pyrimi-dines. XIII. Inhibition of thymidylate synthetase. J Biol Chem. 1961;236:3006–13.
Hollande E, Levrat Di Donato JH et al. Calcium phosphate deposits in domes of human pancreatic adenocarcinoma (Capan-1) cell cultures. Bio Cell. 1990;69:191–203.
Ingebritsen TS, Cohen P. The protein phosphatases involved in cellular regulation. I. Classification and substrate specifi-cities. Eur J Biochem. 1983;132:255–61.
Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature. 1970;227:168–70.
Jiang JB, Hesson DP, Dusak BA, Dexter DL, Kang GH, Hamel E. Synthesis and biological evaluation of 2-styrylquinazolin-4 (3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J Med Chem. 1990;33:1721–8.
Kyriazis AP, Kyriazis AA, Scarpelli DG, Fögh J, Rao MS, Lepera R. Human pancreatic adenocarcinoma cell line Capan-1 in tissue culture and the nude mouse. Morpholo-gic, biologic and biochemical characteristics. Am J Pathol. 1982;106:250–60.
Levitzki A. Signal-transduction therapy. A novel approach to disease management. Eur J Biochem. 1994;226:1–13.
Ludt J, Tonnessen TI, Sandvig K, Olsnes S. Evidence for involvement of protein kinase C in regulation of intracellu-lar pH by Cl-/HCO3 - antiport. J Membrane Biol. 1991;119: 179–86.
Mahieu I, Becq F, Wolfensberger T, Gola M, Carter N, Hollande E. The expression of carbonic anhydrases II and IV in the human pancreatic cancer cell line (Capan-1) is associated with bicarbonate ion channels. Biol Cell. 1994; 81:131–41.
Malet-Martino M-C, Faure F, Vialaneix J-P, Palévody C, Hollande E, Martino R. Non-invasive fluorine 19-NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. Cancer Che-mother Pharmacol. 1986;18:5-10
Mullivor RA, Plutkin LI, Harris H. Differential inhibition of the products of the human alkaline phosphatase loci. Ann Hum Genet. 1978;42:1–13.
Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988; 334:661–5.
Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995;9:484–96.
Pawson T. Introduction: protein kinases. FASEB J. 1994;8: 1112–3.
Ricouart A, Gesquiere JC, Tartar A, Sergheraert C. Design of potent protein kinase inhibitors using the bisubstrate ap-proach. J Med Chem. 1991;34:73–8.
Roberts JJ, Pascoe JM. Cross-linking of complementary strands of DNA in mammalian cells by antitumour plati-num compounds. Nature. 1972;235:282–4.
Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature. 1969;222:385–6.
Sander J, Myatt L. Regulation of prostaglandin-E2 synthesis in human amnion by protein kinase-C. Prostaglandins. 1990; 39:355–63.
Skoufias DA, Wilson L. Mechanism of inhibition of microtu-bule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry. 1992;31:738–46.
Tamaki T, Nomoto H, Takahashi I, Yato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospho-lipid/Ca2+ dependent protein kinase. Biochem Biophys Res Commun. 1986;135:397–403.
Tarasiuk J, Kolodziejczyk P, Borowski E. Enzymatic studies of the effect of Cu (II) on oxygen radical production stimu-lated by daunorubicin and ametantrone. Biochem Pharma-col. 1990;39:1405–10.
Walsh DA, Van Patten SM. Multiple pathway signal trans-duction by the cAMP-dependent protein kinase. FASEB J. 1994;8:1227–36.
Walton KM, Dixon JE. Protein tyrosine phosphatase. Annu Rev Biochem. 1993;62:101–20.
Wurzer JC, Tallarida RJ, Sirover MA. New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther. 1994;269:39–43.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gonindard, C., Bergonzi, C., Denier, C. et al. Synthetic hispidin, a PKC inhibitor, is more cytotoxic toward cancer cells than normal cells in vitro. Cell Biol Toxicol 13, 141–153 (1997). https://doi.org/10.1023/A:1007321227010
Issue Date:
DOI: https://doi.org/10.1023/A:1007321227010